2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

Changho Choi, Sandeep K Ganji, Ralph J DeBerardinis, Kimmo J Hatanpaa, Dinesh Rakheja, Zoltan Kovacs, Xiao-Li Yang, Tomoyuki Mashimo, Jack M Raisanen, Isaac Marin-Valencia, Juan M Pascual, Christopher J Madden, Bruce E Mickey, Craig R Malloy, Robert M Bachoo, Elizabeth A Maher, Changho Choi, Sandeep K Ganji, Ralph J DeBerardinis, Kimmo J Hatanpaa, Dinesh Rakheja, Zoltan Kovacs, Xiao-Li Yang, Tomoyuki Mashimo, Jack M Raisanen, Isaac Marin-Valencia, Juan M Pascual, Christopher J Madden, Bruce E Mickey, Craig R Malloy, Robert M Bachoo, Elizabeth A Maher

Abstract

Mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) have been shown to be present in most World Health Organization grade 2 and grade 3 gliomas in adults. These mutations are associated with the accumulation of 2-hydroxyglutarate (2HG) in the tumor. Here we report the noninvasive detection of 2HG by proton magnetic resonance spectroscopy (MRS). We developed and optimized the pulse sequence with numerical and phantom analyses for 2HG detection, and we estimated the concentrations of 2HG using spectral fitting in the tumors of 30 subjects. Detection of 2HG correlated with mutations in IDH1 or IDH2 and with increased levels of D-2HG by mass spectrometry of the resected tumors. Noninvasive detection of 2HG may prove to be a valuable diagnostic and prognostic biomarker.

Figures

Figure 1
Figure 1
(a) Quantum-mechanically calculated spectra of the 2HG H4 resonances, at 3T, are displayed vs. TE1 and TE2 of PRESS (subecho times of the first and second slice-selective 180° radio-frequency pulses, respectively). (b) Calculated difference-edited multiplets of the 2HG H2 resonance are plotted vs. subecho times TE1 and TE2 of scalar difference editing. Shown for each TE1-TE2 pair are, top to bottom, E180-on (brown) and E180-off (green) subspectra, and difference between the two subspectra (blue). Here E180 denotes editing 180° pulses tuned to 1.9 p.p.m. PRESS and edited spectra are all broadened to singlet line width of 4 Hz. Spectra in (a) and (b) are scaled equally for direct comparison. Signal reduction due to T2 relaxation effects was not included in the calculations. (c) Calculated and phantom spectra of 2HG for PRESS and difference editing. The echo times were 97 and 106 ms for PRESS and editing. The concentrations of 2HG and glycine in the phantom were both 10 mM (pH = 7.0). Spectra are scaled with respect to the glycine singlet at 3.55 p.p.m..
Figure 2
Figure 2
In vivo single-voxel localized PRESS spectra from normal brain (a) and tumors (b-f), at 3T, are shown together with spectral fits (LCModel) and the components of 2HG, GABA, glutamate, and glutamine, and voxel positioning (2×2×2 cm3). Spectra are scaled with respect to the water signal from the voxel. Vertical lines are drawn at 2.25 p.p.m. to indicate the H4 multiplet of 2HG. Shown in brackets is the estimated metabolite concentration (mM) ± standard deviation. Abbreviations: Cho, choline; Cr, creatine; NAA, N-acetylaspartate; Glu, glutamate; Gln, glutamine; GABA, γ-aminobutyric acid; Gly, glycine; Lac, lactate; Lip, lipids. Scale bars, 1 cm.
Figure 3
Figure 3
(a) LCModel fitting results (fits and residuals) of PRESS spectra obtained with basis set with or without 2HG. Data are displayed in the order of increasing 2HG estimates, top to bottom. (b) PRESS and difference-edited spectra from four subjects are shown in pairs, together with LCModel fits and 2HG signal components. Vertical lines are drawn at 2.25 and 4.02 p.p.m. in the PRESS and edited spectra, respectively.
Figure 4
Figure 4
(a) Multi-voxel imaging spectra from a patient with a WHO Grade 3 oligodendroglioma patient are displayed on top of the T2w-FLAIR image. The grid size is 1×1 cm, with slice thickness 1.5 cm. The spectra are displayed between 4.1 – 1.8 p.p.m. (left to right). (b,c) Two representative spectra (one from the tumor and another from the contralateral normal brain) are shown together with LCModel fits and residuals. (d) The estimated concentrations of 2HG, choline and NAA in individual voxels were color coded for comparison. The NAA level in gray matter in normal brain was assumed to be 12 mM. Scale bars, 1 cm.

References

    1. Balss J, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597–602.
    1. Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773.
    1. Dang L, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–744.
    1. Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–567.
    1. Christensen BC, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst. 2011;103:143–153.
    1. Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812.
    1. Von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. Brain Pathology. 2011;21:74–87.
    1. Bottomley PA. US Patent. United States: 1984. Selective volume method for performing localized NMR spectroscopy. Vol. 4 228.
    1. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11:266–272.
    1. Bal D, Gryff-Keller A. 1H and 13C NMR study of 2-hydroxyglutaric acid and lactone. Magnetic Resonance Chemistry. 2002;40:533–536.
    1. Krawczyk H, Gradowska W. Characterisation of the 1H and 13C NMR spectra of N-acetylaspartylglutamate and its detection in urine from patients with Canavan disease. J Pharm Biomed Anal. 2003;31:455–463.
    1. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000;13:129–153.
    1. Ernest RR, Bodenhausen G, Wokaun A. Principles of nuclear magnetic resonance in one and two dimensions. Oxford: Clarendon Press; 1987.
    1. Thompson RB, Allen PS. Sources of variability in the response of coupled spins to the PRESS sequence and their potential impact on metabolite quantification. Magn Reson Med. 1999;41:1162–1169.
    1. Choi C, et al. Improvement of resolution for brain coupled metabolites by optimized (1)H MRS at 7T. NMR Biomed. 2010;23:1044–1052.
    1. Gillies RJ, Raghunand N, Garcia-Martin ML, Gatenby RA. pH imaging. A review of pH measurement methods and applications in cancers. IEEE Eng Med Biol Mag. 2004;23:57–64.
    1. Griffiths JR. Are cancer cells acidic? Br J Cancer. 1991;64:425–427.
    1. McLean LA, Roscoe J, Jorgensen NK, Gorin FA, Cala PM. Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am J Physiol Cell Physiol. 2000;278:C676–C688.
    1. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672–679.
    1. Mlynarik V, Gruber S, Moser E. Proton T (1) and T (2) relaxation times of human brain metabolites at 3 Tesla. NMR Biomed. 2001;14:325–331.
    1. Traber F, Block W, Lamerichs R, Gieseke J, Schild HH. 1H metabolite relaxation times at 3.0 tesla: Measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J Magn Reson Imaging. 2004;19:537–545.
    1. Ganji SK, et al. T2 measurement of J-coupled metabolites in the human brain at 3T. NMR Biomed. 2011 In Press.
    1. Norton WT, Poduslo SE, Suzuki K. Subacute sclerosing leukoencephalitis. II. Chemical studies including abnormal myelin and an abnormal ganglioside pattern. J Neuropathol Exp Neurol. 1966;25:582–597.
    1. Keevil SF, et al. Absolute metabolite quantification by in vivo NMR spectroscopy: II. A multicentre trial of protocols for in vivo localised proton studies of human brain. Magn Reson Imaging. 1998;16:1093–1106.
    1. Tong Z, Yamaki T, Harada K, Houkin K. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. Magn Reson Imaging. 2004;22:1017–1024.
    1. Sener RN. L-2 hydroxyglutaric aciduria: proton magnetic resonance spectroscopy and diffusion magnetic resonance imaging findings. J Comput Assist Tomogr. 2003;27:38–43.
    1. Goffette SM, et al. L-2-Hydroxyglutaric aciduria: clinical, genetic, and brain MRI characteristics in two adult sisters. Eur J Neurol. 2006;13:499–504.
    1. Choi C, et al. Measurement of glycine in the human brain in vivo by (1) H-MRS at 3 T: application in brain tumors. Magn Reson Med. 2011
    1. Maher EA, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006;66:11502–11513.
    1. Rakheja D, Mitui M, Boriack RL, DeBerardinis RJ. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. Pediatr Blood Cancer. 2011;56:379–383.
    1. Rakheja D, et al. Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate. Tumour Biol. 2011;32:325–333.

Source: PubMed

3
S'abonner